Manufacturing Complexity and Scale-Up: Hidden Contributors to Drug Safety Risk

Drug safety is typically assessed through clinical outcomes: adverse events, dose-response relationships, and postmarketing surveillance. This commentary argues that this framing, while appropriate, can obscure manufacturing's role in determining what patients actually receive. Its purpose is to examine drug safety from a Chemistry, Manufacturing, and Controls (CMC) perspective and to make the case for integrating manufacturing considerations more explicitly into safety assessment across the product lifecycle.

The analysis draws on engineering and CMC experience, established regulatory guidance, and published examples of manufacturing-related safety events, rather than on clinical trial data or pharmacovigilance analysis. It examines how manufacturing complexity, contamination and impurity risk, and process scale-up introduce safety-relevant uncertainty that evolves throughout the product lifecycle, and how existing regulatory and quality tools address it.

Manufacturing complexity creates latent safety risks through operational variability and system design. Contamination and impurities function as system-level hazards rather than isolated quality failures. Scale-up constitutes a critical inflection point at which assumptions about process robustness are stress-tested under real-world constraints. These risks are difficult to detect through clinical frameworks because they are often low frequency, system driven, and surfaced through quality investigations rather than adverse event reporting. Existing tools, including continuous manufacturing, process analytical technology, real-time release testing, quality by design, and lifecycle-management guidance, mitigate but do not eliminate this uncertainty.

Recognizing manufacturing as part of the drug safety system, and coordinating CMC and pharmacovigilance functions during process changes and scale-up would strengthen patient protection by addressing risks that originate upstream of clinical use but manifest as patient exposure over time.